Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SANAthis companySana Biotechnology, Inc.	$2.35	-4.24×	6.41×	0×	-4.48×	-101.4%	0.0%	0.0%	0.0%	-151.8%	-54.1%	-14.0%	0.49×	-0.03×	0×	1.89×	0.0%	1	-6.29	1	D+
ALLOAllogene Therapeutics, Inc.	$1.02	-1.57×	1.03×	0×	-1.88×	-114.2%	0.0%	0.0%	0.0%	-65.3%	-52.8%	-49.5%	0.28×	-0.18×	-192.5×	7.93×	0.0%	4	-3.65	2	C
ATRAAtara Biotherapeutics, Inc.	$8.36	6.93×	-5.89×	1.88×	7.02×	-5049.6%	82.4%	29.7%	27.1%	-84.9%	222.7%	-22.4%	-1.37×	1.15×	9.46×	0.82×	0.0%	1	-135.86	2	C
BEAMBeam Therapeutics Inc.	$26.95	-34.22×	2.21×	19.62×	-196.25×	-229.8%	84.0%	-274.6%	-57.2%	-6.5%	-27.4%	-13.1%	0.24×	0.08×	-8.77×	13.09×	0.0%	2	4.01	1	C-
CGEMCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
DTILPrecision BioSciences, Inc.	$10.73	-1.17×	0.58×	1.56×	0.68×	-257.3%	100.0%	-152.2%	-133.4%	-49.6%	-35.5%	-123.6%	0.31×	1.93×	-36.67×	13.32×	0.0%	3	-4.84	1	C-
Peer median	—	-1.57×	1.03×	1.56×	-1.88×	-229.8%	82.4%	0.0%	0.0%	-53.8%	-35.5%	-28.8%	0.24×	0.39×	-8.77×	10.25×	0.0%	2	-3.65	2	—